4 recruiting, 1 active not recruiting, 1 completed, 1 not yet recruiting. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 4, Active not recruiting 1, Completed 1, Not yet recruiting 1, Terminated 1, Withdrawn 1 |
| Phase 2 | 4 | Recruiting 2, Not yet recruiting 1, Withdrawn 1 |
Follow SLE: new trials by email Literature Review of SLE trials Research Report on SLE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of CRC01 in Participants With Severe, Refractory Systemic Lupus Erythematosus CRC01 - Lupus Nephritis, Lupus Nephritis (LN) | Phase 1 / Phase 2 | Not yet recruiting | Curocell Inc. | 39 | 2026-02-01 | 2026-01-23 |
| CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus CART19 - SLE, Systemic Lupus Erythematosus (SLE) | Phase 1 / Phase 2 | Recruiting | Children's Hospital of Philadelphia | 24 | 2025-05-06 | 2026-09-24 |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus CLN-978 - SLE, SLE (Systemic Lupus) | Phase 1 | Recruiting | Cullinan Therapeutics Inc. | 24 | 2025-01-21 | 2026-10-26 |
| UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients Physical examination, Electrocardiogram, SF-36 questionnaire - SLE, Lupus | Phase 1 | Recruiting | LiveKidney.Bio | 10 | 2025-01-07 | 2025-09-11 |
| Phase 1b/2a in SLE With Budoputug budoprutug - Systemic Lupus Erythematosus, SLE | Phase 1 / Phase 2 | Withdrawn | Tenet Medicines | 2025-01-01 | 2024-10-16 | |
| A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. APG-2575, Placebo - SLE | Phase 1 / Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 40 | 2024-08-09 | 2025-12-16 |
| AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus AB-101, Cyclophosphamide, Fludarabine - Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | Phase 1 | Active not recruiting | Artiva Biotherapeutics, Inc. | 51 | 2024-04-03 | 2025-12-10 |
| 3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus BR-DIM, Placebo - SLE | Phase 1 | Terminated | Northwell Health | 6 | 2016-01-01 | 2016-02-01 |
| Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis Tacrolimus, cyclophosphamide - SLE, Lupus Nephritis | Phase 1 | Completed | Zhejiang University | 40 | 2003-03-01 | 2011-08-23 |
Lupus Erythematosus, Systemic (6) · Lupus Nephritis (4) · Kidney Failure, Chronic (1) · Renal Insufficiency (1)
Autoimmune Diseases (7) · Connective Tissue Diseases (7) · Immune System Diseases (7) · Skin and Connective Tissue Diseases (7) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Glomerulonephritis (4) · Kidney Diseases (4) · Male Urogenital Diseases (4) · Nephritis (4) · Urogenital Diseases (4) · Urologic Diseases (4) · Chronic Disease (1) · Disease Attributes (1) · Lupus Erythematosus, Systemic (1)
Cyclophosphamide (2) · 3,3'-diindolylmethane (1) · CTL019 chimeric antigen receptor (1) · Electrocardiography (1) · Lisaftoclax (1) · Physical Examination (1) · Pregnancy Tests (1) · Rituximab (1) · Tacrolimus (1) · Urinalysis (1) · fludarabine (1) · obinutuzumab (1)
Artiva Biotherapeutics, Inc. (1) · Ascentage Pharma Group Inc. (1) · Children's Hospital of Philadelphia (1) · Cullinan Therapeutics Inc. (1) · Curocell Inc. (1) · LiveKidney.Bio (1) · Northwell Health (1) · Tenet Medicines (1) · Zhejiang University (1)
United States (4) · Australia (1) · Bulgaria (1) · China (1) · France (1) · Georgia (1) · Germany (1) · Moldova (1) · Romania (1) · Spain (1)
Caitlin Elgarten, MD (1) · Jianghua Chen, MD (1) · Michael Saddekni, M.D., PgDip, BCMAS (1) · Richard Furie, MD (1) · Sheng Chen, Ph.D (1)